← Leaderboards
Jim Zapf
Visionary Pharmaceuticals, Inc.
$1,732,547
Attributed
$2,478,865
Total exposure
4
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $824.7K · FY2014–21$1M$750K$500K$250K$0
'14
'15
'16
'17
'18
'19
'20
'21
Funding mix
By agency
NIH$2,478,865 · 4
By mechanism
R44$1,492,636 · 1
R43$986,229 · 3
Top collaborators
- Gordon Alton2 shared
Others in their field
Top investigators on “Cells”
- Lawrence Corey · Fred Hutchinson Cancer Center$536,344,731
- Barton F Haynes · Duke University$457,457,619
- David Heimbrook · Leidos Biomedical Research, Inc.$454,789,509
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$299,104,942
- Dennis R. Burton · Scripps Research Institute$278,781,854
- Mary M Horowitz · Medical College Of Wisconsin$237,383,608
Research focus
CellsTreatment EfficacyIn VitroSmall Business Innovation Research GrantPropertyPharmaceutical ChemistrySeriesBaseBiological AvailabilityDrug KineticsPharmacologyUnited StatesStandard Of CareAnimal ModelLead SeriesTargeted TreatmentResistanceIn VivoCessation Of LifePharmaceutical PreparationsBiological MarkersLeadNuclear ReceptorsOral
Grant awards (7)
Development of inhibitors of the SGK1 kinase, a critical target in anaplastic thyroid cancer$86,262
R43 · FY2021 · CA · contact PI
Development of inhibitors of the SGK1 kinase, a critical target in anaplastic thyroid cancer$300,000
R43 · FY2019 · CA · contact PI
Development of dual inhibitors of the kinases SGK1 and AKT1 for blockade of a critical pathway in triple-negative breast cancer$299,982
R43 · FY2019 · CA · contact PI
Identification of RORg drug candidates for the treatment of NASH$156,503
R43 · FY2017 · DK · contact PI
Identification of RORg drug candidates for the treatment of NASH$143,482
R43 · FY2016 · DK · contact PI
The Development of RORgt Immunomodulators Targeting the TH17 Axis in IBD- Phase 2$667,910
R44 · FY2015 · DK
The Development of RORgt Immunomodulators Targeting the TH17 Axis in IBD- Phase 2$824,726
R44 · FY2014 · DK